Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects.

about

Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects.

Item

http://www.wikidata.org/entity/Q48020769

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Effects of Rifampin on the Pha ...... defylline in Healthy Subjects.

@en

Effects of Rifampin on the Pha ...... defylline in Healthy Subjects.

@nl

type

Item

label

Effects of Rifampin on the Pha ...... defylline in Healthy Subjects.

@en

Effects of Rifampin on the Pha ...... defylline in Healthy Subjects.

@nl

prefLabel

Effects of Rifampin on the Pha ...... defylline in Healthy Subjects.

@en

Effects of Rifampin on the Pha ...... defylline in Healthy Subjects.

@nl

P1476

Effects of Rifampin on the Pha ...... defylline in Healthy Subjects.

@en

P2093

Douglas Greene

http://www.w3.org/2001/XMLSchema#string

Marc Cantillon

http://www.w3.org/2001/XMLSchema#string

Maria Vergeire

http://www.w3.org/2001/XMLSchema#string

Mayumi Mukai

http://www.w3.org/2001/XMLSchema#string

Tatsuo Uchimura

http://www.w3.org/2001/XMLSchema#string

Xiaoping Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys

Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP

Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist

Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.

Rifampin and rifabutin drug interactions: an update.

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies.

Pharmacokinetic interactions with rifampicin : clinical relevance.

Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.

Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.

P304

193-201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.1003

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28881378

http://www.w3.org/2001/XMLSchema#string

P932

5811788

http://www.w3.org/2001/XMLSchema#string